Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15349909 | 0.78 | F2RL3 (0.35) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL5891959 | 0.78 | POLB (0.38) | — | |
| SCHEMBL31568981 | 0.74 | KDM4C (0.32) | KDM4CNPC1RAB9A | |
| SCHEMBL29732016 | 0.74 | KDM4C (0.32) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL29757581 | 0.74 | NPC1 (0.36) | KDM4CNPC1RAB9AL3MBTL1 | |
| SCHEMBL21594074 | 0.74 | NPC1 (0.36) | KDM4CNPC1RAB9AL3MBTL1 | |
| SCHEMBL8566097 | 0.74 | L3MBTL1 (0.32) | KDM4CNPC1RAB9AL3MBTL1 | |
| SCHEMBL23851287 | 0.73 | KDM4C (0.33) | KDM4CNPC1RAB9AL3MBTL1 | |
| SCHEMBL20524357 | 0.73 | KDM4C (0.30) | KDM4CNPC1RAB9A | |
| SCHEMBL23851286 | 0.73 | KDM4C (0.33) | KDM4CNPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841086-B1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3841086-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020041301-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | KDM4C 4786/4885NPC1 477/4885RAB9A 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.